These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23703545)

  • 1. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection.
    Li Y; Ma S; Tang L; Li Y; Wang W; Huang X; Lai Q; Zhang M; Sun J; Li CK; Abbott WG; Naoumov NV; Zhang Y; Hou J
    Hepatology; 2013 Oct; 58(4):1277-86. PubMed ID: 23703545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
    Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
    J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
    Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
    Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tfh cell-mediated humoral immune response and HBsAg level can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon-α therapy.
    Zhang L; Zhang M; Li H; Chen Z; Luo A; Liu B; Chen M; Peng M; Ren H; Hu P
    Mol Immunol; 2016 May; 73():37-45. PubMed ID: 27037894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion.
    Yuen MF; Wong DK; Zheng BJ; Chan CC; Yuen JC; Wong BC; Lai CL
    J Viral Hepat; 2007 Apr; 14(4):269-75. PubMed ID: 17381719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating PD-1
    Zhang L; Li H; Ren H; Hu P
    Mol Immunol; 2018 Nov; 103():270-278. PubMed ID: 30340072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation.
    Tseng TC; Liu CJ; Su TH; Yang HC; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2012 Nov; 206(10):1521-31. PubMed ID: 22966125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
    Yang X; Li J; Liu J; Gao M; Zhou L; Lu W
    Medicine (Baltimore); 2017 Jun; 96(23):e7064. PubMed ID: 28591041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B.
    Li J; Jia M; Liu Y; She W; Li L; Wang J; Jiang W
    Liver Int; 2015 Mar; 35(3):834-45. PubMed ID: 24814578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between the changes in immune cells and HBeAg loss following antiviral treatment in chronic hepatitis B patients].
    Zheng Q; Zhu YY; Chen J; Liu YR; You J; Zeng DW; Lin S; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2012 Nov; 20(11):801-6. PubMed ID: 23206296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL13-mediated recruitment of intrahepatic CXCR5
    Li Y; Tang L; Guo L; Chen C; Gu S; Zhou Y; Ye G; Li X; Wang W; Liao X; Wang Y; Peng X; Liu G; Zhang X; Sun J; Peng J; Hou J
    J Hepatol; 2020 Mar; 72(3):420-430. PubMed ID: 31610223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-33 Enhances Humoral Immunity Against Chronic HBV Infection Through Activating CD4(+)CXCR5(+) TFH Cells.
    Zhao PW; Shi X; Li C; Ayana DA; Niu JQ; Feng JY; Wang J; Jiang YF
    J Interferon Cytokine Res; 2015 Jun; 35(6):454-63. PubMed ID: 25714983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients.
    Vyas AK; Sharma BC; Sarin SK; Trehanpati N
    Liver Int; 2018 Jan; 38(1):38-49. PubMed ID: 28500636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
    Rico MA; Quiroga JA; Subirá D; Castañón S; Esteban JM; Pardo M; Carreño V
    Hepatology; 2001 Jan; 33(1):295-300. PubMed ID: 11124848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.
    Wang GQ; Ding YP; Dong YH
    J Viral Hepat; 2013 Apr; 20 Suppl 1():9-17. PubMed ID: 23458520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
    Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
    Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment.
    Li C; Ji H; Cai Y; Ayana DA; Lv P; Liu M; Jiang Y
    J Interferon Cytokine Res; 2013 Oct; 33(10):612-8. PubMed ID: 23697556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice.
    Lin B; Ha NB; Liu A; Trinh HN; Nguyen HA; Nguyen KK; Ahmed A; Keeffe EB; Garcia RT; Garcia G; Nguyen MH
    J Gastroenterol Hepatol; 2013 May; 28(5):855-60. PubMed ID: 23278507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.